-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On January 13, 2022, Rubius Therapeutics announced that its Phase 1/2 clinical trial of RTX-224, a red blood cell therapy designed to broadly stimulate the immune system, has completed the first patient dosing for For the treatment of certain patients with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) cancer, and triple-negative breast cancer
.
Rubius aims to bioengineer red blood cells to create an entirely new class of cellular drugs for the treatment of cancer and autoimmune diseases
.
RTX-224 is an allogeneic red blood cell therapy engineered to express 4-1BBL and IL-12 that activates CD4-positive, CD8-positive T cells, and natural killer (NK) cells by stimulating the 4-1BB and IL-12 pathways and antigen-presenting cells (APCs) to generate robust anti-tumor immune responses
.
Image source: Rubius' official website This open-label, multi-center, multi-dose dose-escalation and expansion Phase 1/2 clinical trial aims to determine the efficacy of RTX-224 in certain adult patients with relapsed/refractory or locally advanced solid tumors Safety, tolerability, pharmacokinetics, maximum tolerated dose, and recommended Phase 2 dose and dosing schedule
in
The trial will also assess pharmacodynamic changes from baseline in immune cell populations, and antitumor activity
.
"We expect RTX-224 to generate broad and robust antitumor T cell responses and innate immune responses, showing anticancer activity in tumors sensitive to T cell killing
.
"Given RTX-224's mechanism of action and the comprehensive preclinical data we have obtained to date, we believe that RTX-224 has the potential to be a promising candidate for certain advanced solid tumors.
" effective treatment
.
"Reference: [1] Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors.
Retrieved January 13, 2022, from https://ir .
rubiustx.
com/news-releases/news-release-details/rubius-therapeutics-announces-dosing-first-patient-phase-12-0Disclaimer: WuXi AppTec content team focuses on global biomedical health research
progress.
This
article For the purpose of information exchange only, the opinions in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the opinions in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
.
Rubius aims to bioengineer red blood cells to create an entirely new class of cellular drugs for the treatment of cancer and autoimmune diseases
.
RTX-224 is an allogeneic red blood cell therapy engineered to express 4-1BBL and IL-12 that activates CD4-positive, CD8-positive T cells, and natural killer (NK) cells by stimulating the 4-1BB and IL-12 pathways and antigen-presenting cells (APCs) to generate robust anti-tumor immune responses
.
Image source: Rubius' official website This open-label, multi-center, multi-dose dose-escalation and expansion Phase 1/2 clinical trial aims to determine the efficacy of RTX-224 in certain adult patients with relapsed/refractory or locally advanced solid tumors Safety, tolerability, pharmacokinetics, maximum tolerated dose, and recommended Phase 2 dose and dosing schedule
in
The trial will also assess pharmacodynamic changes from baseline in immune cell populations, and antitumor activity
.
"We expect RTX-224 to generate broad and robust antitumor T cell responses and innate immune responses, showing anticancer activity in tumors sensitive to T cell killing
.
"Given RTX-224's mechanism of action and the comprehensive preclinical data we have obtained to date, we believe that RTX-224 has the potential to be a promising candidate for certain advanced solid tumors.
" effective treatment
.
"Reference: [1] Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors.
Retrieved January 13, 2022, from https://ir .
rubiustx.
com/news-releases/news-release-details/rubius-therapeutics-announces-dosing-first-patient-phase-12-0Disclaimer: WuXi AppTec content team focuses on global biomedical health research
progress.
This
article For the purpose of information exchange only, the opinions in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the opinions in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
